EQ Key Statistics, Chart & Performance
The current stock price of EQ is 1.4 USD. In the past month the price increased by 45.83%. In the past year, price increased by 101.73%.
EQ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.12 | 402.80B | ||
| AMGN | AMGEN INC | 15.15 | 178.45B | ||
| GILD | GILEAD SCIENCES INC | 15.16 | 154.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.52 | 116.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.32 | 81.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 799.47 | 53.87B | ||
| INSM | INSMED INC | N/A | 37.48B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.44 | 25.63B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.47 | 22.12B | ||
| INCY | INCYTE CORP | 15.69 | 19.77B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.32B |
Related stock screener links
About EQ
Company Profile
Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 35 full-time employees. The company went IPO on 2018-10-12. The company is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.
Company Info
EQUILLIUM INC
2223 Avenida de La Playa Ste 105
La Jolla CALIFORNIA 92037 US
CEO: Bruce D. Steel
Employees: 35
Phone: 18584125302
EQUILLIUM INC / EQ FAQ
Can you describe the business of EQUILLIUM INC?
Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 35 full-time employees. The company went IPO on 2018-10-12. The company is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.
What is the current price of EQ stock?
The current stock price of EQ is 1.4 USD. The price increased by 21.74% in the last trading session.
Does EQ stock pay dividends?
EQ does not pay a dividend.
How is the ChartMill rating for EQUILLIUM INC?
EQ has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is EQUILLIUM INC (EQ) stock traded?
EQ stock is listed on the Nasdaq exchange.
How is the market expecting EQ stock to perform?
11 analysts have analysed EQ and the average price target is 2.55 USD. This implies a price increase of 82.14% is expected in the next year compared to the current price of 1.4.
Can you provide the PE ratio for EQ stock?
EQUILLIUM INC (EQ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.62).
EQ Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to EQ. When comparing the yearly performance of all stocks, EQ is one of the better performing stocks in the market, outperforming 92.94% of all stocks.
EQ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EQ. No worries on liquidiy or solvency for EQ as it has an excellent financial health rating, but there are worries on the profitability.
EQ Financial Highlights
Over the last trailing twelve months EQ reported a non-GAAP Earnings per Share(EPS) of -0.62. The EPS decreased by -342.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.76% | ||
| ROE | -78.92% | ||
| Debt/Equity | 0 |
EQ Forecast & Estimates
11 analysts have analysed EQ and the average price target is 2.55 USD. This implies a price increase of 82.14% is expected in the next year compared to the current price of 1.4.
For the next year, analysts expect an EPS growth of -231.39% and a revenue growth -100% for EQ